Vanguard Therapeutics Overview

  • Founded
  • 2009
  • Status
  • Private
  • Employees
  • 2
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 4

Vanguard Therapeutics General Information


Developer of therapy for sickle cell disease that targets the process that drives sickle cell disease -- abnormal blood flow. The company's oral drug that blocks the cell adhesion molecule P-selectin addresses the problem of sickle red blood cells sticking to the vascular endothelium, helping to improve blood flow, mitigate acute painful crises, and improve the quality of life of patients with sickle cell disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Primary Office
  • 108 Eagle Trace Drive
  • Half Moon Bay, CA 94019
  • United States
+1 (415) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vanguard Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 01-Jan-2015 Completed Startup
3. Grant 15-Feb-2014 00000 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator 01-Apr-2014 Completed Startup
To view Vanguard Therapeutics’s complete valuation and funding history, request access »

Vanguard Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Stephen Embury MD Founder, Chief Executive Officer & Chairman
To view Vanguard Therapeutics’s complete executive team members history, request access »

Vanguard Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vanguard Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BayBio FAST Accelerator/Incubator 000 0000 000000 0
California Institute for Quantitative Biosciences Accelerator/Incubator 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
To view Vanguard Therapeutics’s complete investors history, request access »